SCHEMBL20153238

SCHEMBL20153238

CSc1nc(NC(=O)OC2CCC(F)(F)CC2)cc(N2CCOCC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
GAA P10253 3/20 0.37
ALDH1A1 P00352 2/20 0.37
FFAR4 Q5NUL3 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
THRB P10828 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAP4K1 Q92918 1/20 0.37
PDE4B Q07343 1/20 0.36
AURKA O14965 1/20 0.36
AURKB Q96GD4 1/20 0.36
NAPEPLD Q6IQ20 1/20 0.36
EGFR P00533 1/20 0.36
ERBB3 P21860 1/20 0.36
RAB9A P51151 1/20 0.36
TP53 P04637 1/20 0.36
KIF18A Q8NI77 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21143964 0.87 FFAR4 (0.35) KMT2AFFAR4MEN1MAP4K1NAPEPLD
SCHEMBL20399779 0.84 RAF1 (0.39) KMT2AADORA2AADORA1GAAALDH1A1
SCHEMBL19687232 0.80 KMT2A (0.51) KMT2AFFAR4KDM4EPDE4B
SCHEMBL21144116 0.80 ADORA2A (0.39) KMT2AADORA2AADORA1GAAALDH1A1
SCHEMBL21143614 0.78 IDH1 (0.37) KMT2AADORA2AADORA1GAAALDH1A1
SCHEMBL21144075 0.77 IDH1 (0.44) ADORA2AADORA1GAAALDH1A1EGFR
SCHEMBL21144121 0.77 EGFR (0.34) ADORA2AADORA1GAAALDH1A1MAP4K1
SCHEMBL21143650 0.77 HRH3 (0.36) ADORA2AADORA1NAPEPLDEGFRERBB3
SCHEMBL21144147 0.77 EGFR (0.34) KMT2AADORA2AADORA1GAAALDH1A1
SCHEMBL20153234 0.77 KMT2A (0.58) KMT2AADORA2AADORA1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210380571-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-09 US disclosed
EP-3571193-B1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS INC (US) 2021-12-01 EP disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10717728-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-07-21 US disclosed
US-20190352293-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-11-21 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-10351553-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2019-07-16 US disclosed
US-20180215746-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2018-08-02 US disclosed
WO-2018136917-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. (US) 2018-07-26 WO disclosed
US-9975886-B1 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2018-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KMT2A 1471/4885ADORA2A 1711/4885ADORA1 1011/4885
US-20210380571-A1 POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK10, KCNJ1 KMT2A 817/4885ADORA2A 2201/4885ADORA1 2048/4885
US-10717728-B2 Potassium channel modulators KCNJ2, KCNQ2, KCNJ1 KMT2A 1059/4885ADORA2A 1624/4885ADORA1 1329/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KMT2A 1471/4885ADORA2A 1711/4885ADORA1 1011/4885
US-20190352293-A1 POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK10, KCNJ1 KMT2A 817/4885ADORA2A 2201/4885ADORA1 2048/4885
US-20180215746-A1 POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK10, KCNJ1 KMT2A 817/4885ADORA2A 2201/4885ADORA1 2048/4885
US-10351553-B2 Potassium channel modulators KCNN2, KCNN1, KCNN3 KMT2A 1574/4885ADORA2A 2142/4885ADORA1 2008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.